$10.90
0.848.35%
Last update: Oct 23, 12:31 PM
MiNK Therapeutics Inc (INKT) Stock Price, Quote, News & History
INKTNASDAQ
MiNK Therapeutics' stock rises premarket after announcing a pediatric cancer cell therapy collaboration with C-Further and $1.1 million funding.
You can purchase shares of MiNK Therapeutics (NASDAQ:INKT) through any online brokerage.
Other companies in MiNK Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
MiNK Therapeutics has a consensus price target of $41.67.
The stock price for MiNK Therapeutics (NASDAQ: INKT) is $10.9 last updated October 23, 2026 at 12:31 PM EDT.
There are no upcoming dividends for MiNK Therapeutics.
MiNK Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for MiNK Therapeutics.
MiNK Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated...
